Strong first-quarter results Characterised by revenue growth (2% YoY) and double-digit EPS expansion (11% YoY)nfirm Merck’s effective execution and ability to grow despite challenges. Key brands' robust performance, cost-cutting measures, and disciplined investments contribute to the positive outcome. The이기도 한indicatoris the company’s handling of patent Cliffs, a main concern for investors, by successfully retaining revenues post-expiration ofCOZAAR®/HYZAAR®.However, the poaching of Joe Romanelli, a key IR team member, mayZáve concerns about leadership stability

0